ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "Biomarkers"

Study Probes Utility of Neutrophil Biomarkers in Rheumatoid Arthritis

Elizabeth Hofheinz, MPH, MEd  |  December 14, 2020

Neutrophils, often hailed as guardians against infections, are maligned when it comes to rheumatoid arthritis (RA) due to their role in both the initial stage and disease progression. A new multicenter work, “A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients with Rheumatoid Arthritis,” seeks to expand the literature on this topic.1 The…

Researchers Seek ANCA-Associated Vasculitis Subtype Markers

Larry Beresford  |  October 19, 2020

New research on complement activation in anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis underscores its important role in the patho­genesis of this disease, an autoimmune condition defined by inflammation of small- and medium-caliber blood vessels.1 ANCA testing is commonly performed to help diagnose granulomatosis with polyangiitis and microscopic polyangiitis, both of which are forms of ANCA-associated…

Unified Signature of SLE May Advance Clinical Diagnosis & Biomarker Development

Lara C. Pullen, PhD  |  June 29, 2020

Researchers have identified 93 genes that may play a role in systemic lupus erythematosus (SLE), including 47 genes not previously associated with SLE. Theresulting transcriptome has revealed underappreciated genes and pathways associated with the pathogenesis of SLE…

5 Challenges in the Treatment & Diagnosis of Lupus

Kelly Tyrrell  |  February 13, 2020

A recent study published in Lupus Science & Medicine lays out five of the top barriers impeding progress in lupus diagnosis and treatment.1 The Addressing Lupus Pillars for Health Advancement project (ALPHA), led by the Lupus Foundation of America (LFA), researchers at the Tufts School of Medicine Center for the Study of Drug Development (Tufts…

Emerging Biomarkers for Lupus

Thomas R. Collins  |  January 17, 2020

ATLANTA—When it comes to identifying reliable biomarkers that can predict worsening illness or help point to proper treatment, it’s hard to imagine a more vexing disease than systemic lupus erythematosus (SLE), said Jill P. Buyon, MD, director of the Lupus Center at New York University Langone Medical Center, in the 2019 ACR/ARP Annual Meeting session…

In Green / shutterstock.com

Sjögren’s Syndrome in Kids: Diagnostic Challenges & Treatment Options

Sara M. Stern, MD, Matthew L. Basiaga, DO, MSCE, & Scott M. Lieberman, MD, PhD  |  January 17, 2020

A 14-year-old girl is referred to your office for fatigue and arthralgias. While you’re obtaining her past medical history, she divulges that she has had four episodes of bilateral parotitis, each lasting two weeks. An otolaryngologist evaluated her. She lacked sicca symptoms, had a normal complete blood count (CBC), normal inflammatory markers and a negative…

Progress on Preventing Immune-Related Adverse Events

Mike Fillon  |  November 20, 2019

ATLANTA—One of the hottest topics in medicine is the emerging field of cancer immunotherapy. However, immune-related adverse events (irAEs) are associated with the therapy, and when things go wrong, they can go very, very wrong, said Ryan Sullivan, MD, during the 2019 ACR/ARP Annual Meeting in November. “The guiding principle of cancer immunotherapy is [that]…

Study Says Sjögren’s Patients Have a High Specificity for a Novel Antibody

Mary Beth Nierengarten  |  September 17, 2019

An antibody previously un-recognized in patients with Sjögren’s syndrome may shed new light on the patho­physiology of one of the most troubling and disabling symptoms in many of these patients. Investigators at Johns Hopkins University, Baltimore, found the anti-calponin 3 antibody had a high specificity for Sjögren’s syndrome, particularly among patients with neuropathies.1 “There is…

Phase 2 Results for Mavrilimumab Are In

Mary Beth Nierengarten  |  November 19, 2018

Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA. Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating…

Biomarkers for Knee OA

Gretchen Henkel  |  November 18, 2018

Knee osteoarthritis (OA) accounts for more than 80% of OA disease burden and has doubled in prevalence in the mid-20th century in the U.S. when compared with people who lived during early industrial era (1800s to early 1900s).1 Currently, the diagnostic and treatment armamentaria are limited. Disease progression is measured by joint space narrowing on…

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences